Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.67
(
-0.98%
)
Bitcoin
74,303.38
(
0.49%
)
News Focus
News Focus
Post# of 20689
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 64
Posts 11870
Boards Moderated 0
Alias Born 07/16/2006

jbog

Re: jbog post# 9387

Thursday, 07/19/2012 10:43:23 AM

Thursday, July 19, 2012 10:43:23 AM

Post# of 20689

Sandoz continued to strengthen its number one global position in biosimilars (USD 84 million, +28%, +39% cc), and saw strong momentum across all three of its products – Omnitrope (human growth hormone), Binocrit (epoetin alfa) and Zarzio (filgrastim) – each of which is the leading biosimilar in its respective market segment.




Doesn't $84 mil/q seem like a non event at this point?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM

Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM

Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM

Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM

DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM

Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM

Start posting your company's news
Only $200 per official company press release!